Evaluation clinical, electrocardiographic and laboratory response of reperfusion therapy in patients with first acute myocardial infarction

Myocardial infarction (MI) is one of the most common causes of death and disability in various societies, especially in developed countries, and its complications are one of the main health problems in each country, especially in the big cities and among middle-aged and adult people [1,2]. Acute MI (AMI), which is the most common cause of acute attacks, is often caused due to obstructive coronary artery due to a blood clot, severe spasm of the arteries or atherosclerosis in the coronary arteries. In recent decades, despite of improving public health condition in many countries of the world, the incidence of cardiovascular diseases has become the most important health problem [1-3]. Returning of ST-segment is a good predictor of infarct artery patency and preserves myocardial perfusion in heart tissue level [4,5]. The successful resolution in ST-segment is as an electrocardiographic (ECG) signal of myocardial tissue repair which indicates the progression of infarction [6]. If the primary percutaneous coronary intervention (PCI) is not available, one of the initial treatment of AMI is the prescription of thrombolytic medication, which is considered the primary and preferred method of lifesaving [2,3]. Among thrombolytic medications, streptokinase (SK) due to the opening of the blocked artery by thrombosis and reduction of mortality without any potential hemorrhagic complications is more important [7-9]. Quick start of SK and other thrombolytic medications leads to adjacent of ischemic myocardial perfusion to the infarct region. The success of thrombolysis in clot lysis and creating second reperfusion in saving myocardial ischemic and in preserving of myocardial function plays a key role [8]. The effect of thrombolytic medications in creating myocardial perfusion can be measured by several factors, and angiography is considered as a delayed and invasive method in approaching the patients who received thrombolytic medications.